Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib

BACKGROUND: The ongoing US MM-6 study is investigating in-class transition (iCT) from parenteral bortezomib-based induction to all-oral IRd (ixazomib-lenalidomide-dexamethasone) with the aim of increasing proteasome inhibitor (PI)-based treatment adherence and duration while maintaining patients’ he...

Descripción completa

Detalles Bibliográficos
Autores principales: Manda, Sudhir, Yimer, Habte A., Noga, Stephen J., Girnius, Saulius, Yasenchak, Christopher A., Charu, Veena, Lyons, Roger, Aiello, Jack, Bogard, Kimberly, Ferrari, Renda H., Cherepanov, Dasha, Demers, Brittany, Lu, Vickie, Whidden, Presley, Kambhampati, Suman, Birhiray, Ruemu E., Jhangiani, Haresh S., Boccia, Ralph, Rifkin, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc. 2020
Materias:
Original Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336931/
https://www.ncbi.nlm.nih.gov/pubmed/32912820
http://dx.doi.org/10.1016/j.clml.2020.06.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336931/
https://www.ncbi.nlm.nih.gov/pubmed/32912820
http://dx.doi.org/10.1016/j.clml.2020.06.024

Ejemplares similares